A clinical comparative study of the management of chronic renal failure with Punarnavadi compound
Journal name: AYU (Journal of Research in Ayurveda)
Original article title: A clinical comparative study of the management of chronic renal failure with Punarnavadi compound
AYU is an internationally recognized quarterly journal dedicated to advancing research in Ayurveda. The journal covers a wide range of topics, including clinical and pharmacological research in Ayurveda's eight branches, herbal remedies, phytochemistry, and ethnomedicine.
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
G. S. Prashanth
M. S. Baghel
B. Ravishankar
S. N. Gupta
Miten P. Mehta
Download the PDF file of the original publication
AYU (Journal of Research in Ayurveda):
(An International Quarterly Journal of Research in Ayurveda)
Full text available for: A clinical comparative study of the management of chronic renal failure with Punarnavadi compound
Year: 2010 | Doi: 10.4103/0974-8520.72388
Copyright (license): CC BY-NC-SA 4.0
Summary of article contents:
India like any other country is facing a silent epidemic of chronic renal failure (CRF)- a facet of the health transition associated with industrialization partly fuelled by increase in sedentary lifestyle, low birth weight and malnutrition. Increasing figures by many folds seen is posing a difficult situation to overcome with respect to economy and health of the working and earning population of the nation. There is an urgent need to explore, highlight new interventions and modify modifiable risk factors as a basis for treatment strategies to prevent the development and progression of CRF. The present study was taken up to evaluate the role of trial formulation tab. Punarnavadi compound in the management of chronic renal failure. This was an open clinical comparative study in controlled circumstances wherein 67 patients were studied for two months in three groups- Group A (allopathic control), Group B (ayurvedic control) and Group C (ayurvedic test). It was a multi-centric study; patients were registered from Anandababa charitable dialysis centre, Jamnagar, Kayachikitsa O.P.D. of I.P.G.T. and R.A. Jamnagar and P. D. Patel Ayurveda hospital, Nadiad. Results were assessed on 15 parameters using Students (paired) âtâ test. Group A patients showed comparatively better results in eight parameters- weight, platelet count, serum urea, serum uric acid, serum sodium, potassium, chloride and total proteins. Parameter Hemoglobin% showed better results in Group B patients and in Group C patients comparatively better results in six parameters viz.- quality of life (breathlessness, weakness, general functional capacity), total count, serum creatinine and serum calcium - were observed. Throughout the study, trial drug tab. Punarnavadi compound did not show any adverse drug reaction. The results of this study will help in developing a cheap and safe treatment for the management of CRF. Keywords: Chronic kidney disease, chronic renal failure, Punarnavadi compound, ayurvedic management.
Other Health Sciences Concepts:
Discover the significance of concepts within the article: âA clinical comparative study of the management of chronic renal failure with Punarnavadi compoundâ. Further sources in the context of Health Sciences might help you critically compare this page with similair documents:
Statistical analysis, Group A, Quality of life, Sedentary lifestyle, Group (b), Group (c), Diet schedule, Adverse drug reaction, Renal calculi, Low birth weight, Ayurvedic Management, Quality of sleep, Chronic renal failure, End stage renal disease, Chronic Kidney Disease, Hematological Parameters, Working population, Health transition, Clinical comparative study, Bio-chemical parameters, Investigative parameters, Multi-centric study, Chronic ingestion, Renal replacement therapy, Diabetes and hypertension, Tobacco addiction, Polycystic kidney disease, Serum electrolyte.